Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $20.29 Average Price Target from Analysts

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average recommendation of “Hold” by the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $20.2857.

Several brokerages recently commented on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. BTIG Research reduced their target price on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. JMP Securities lowered their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Monday, September 22nd. Finally, Evercore ISI dropped their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd.

Insider Buying and Selling

In related news, CEO Ron Martell purchased 41,000 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average price of $2.43 per share, with a total value of $99,630.00. Following the completion of the acquisition, the chief executive officer owned 74,118 shares in the company, valued at $180,106.74. This trade represents a 123.80% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Svetlana Lucas acquired 20,000 shares of Jasper Therapeutics stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average price of $2.43 per share, for a total transaction of $48,600.00. Following the transaction, the director owned 20,000 shares of the company’s stock, valued at $48,600. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 143,000 shares of company stock valued at $347,490 over the last ninety days. 4.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new position in Jasper Therapeutics during the first quarter worth about $46,000. Marex Group plc purchased a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at approximately $74,000. Engineers Gate Manager LP purchased a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at approximately $78,000. Voleon Capital Management LP acquired a new position in Jasper Therapeutics in the third quarter valued at approximately $50,000. Finally, Goldman Sachs Group Inc. grew its position in Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after acquiring an additional 23,453 shares during the period. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock opened at $1.86 on Wednesday. Jasper Therapeutics has a twelve month low of $1.39 and a twelve month high of $22.99. The firm has a market capitalization of $52.04 million, a PE ratio of -0.32 and a beta of 3.06. The firm’s 50-day moving average price is $1.96 and its 200 day moving average price is $3.01.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12). On average, sell-side analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.